218 related articles for article (PubMed ID: 7913311)
21. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma.
Oda Y; Ohishi Y; Saito T; Hinoshita E; Uchiumi T; Kinukawa N; Iwamoto Y; Kohno K; Kuwano M; Tsuneyoshi M
J Pathol; 2003 Feb; 199(2):251-8. PubMed ID: 12533839
[TBL] [Abstract][Full Text] [Related]
22. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
23. [Multiple drug resistance: a problem in cancer chemotherapy].
Lizano Soberón M; Barrera Rodríquez R
Rev Invest Clin; 1993; 45(5):481-92. PubMed ID: 7907810
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance: P-glycoprotein and its allies--the elusive foes.
Chabner BA; Fojo A
J Natl Cancer Inst; 1989 Jun; 81(12):910-3. PubMed ID: 2567356
[No Abstract] [Full Text] [Related]
25. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins.
Juranka PF; Zastawny RL; Ling V
FASEB J; 1989 Dec; 3(14):2583-92. PubMed ID: 2574119
[TBL] [Abstract][Full Text] [Related]
26. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines.
Utz I; Gekeler V; Ise W; Beck J; Spitaler M; Grunicke H; Hofmann J
Anticancer Res; 1996; 16(1):289-96. PubMed ID: 8615623
[TBL] [Abstract][Full Text] [Related]
27. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
28. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.
Lee JS; Scala S; Matsumoto Y; Dickstein B; Robey R; Zhan Z; Altenberg G; Bates SE
J Cell Biochem; 1997 Jun; 65(4):513-26. PubMed ID: 9178101
[TBL] [Abstract][Full Text] [Related]
29. Multidrug resistance in human cancer.
Goldstein LJ; Pastan I; Gottesman MM
Crit Rev Oncol Hematol; 1992; 12(3):243-53. PubMed ID: 1353966
[No Abstract] [Full Text] [Related]
30. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
31. Characterization of vincristine-resistant HOB1 lymphoma cell line showing the classical MDR phenotype and altered expression of membrane glycoproteins.
Lee WP; Lee CL
Oncology; 1994; 51(1):2-8. PubMed ID: 7903440
[TBL] [Abstract][Full Text] [Related]
32. Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
Coley HM; Labeed FH; Thomas H; Hughes MP
Biochim Biophys Acta; 2007 Apr; 1770(4):601-8. PubMed ID: 17270349
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of multidrug resistance.
Bradley G; Juranka PF; Ling V
Biochim Biophys Acta; 1988 Aug; 948(1):87-128. PubMed ID: 2899442
[No Abstract] [Full Text] [Related]
34. New mechanisms of hormone secretion: MDR-like gene products as extrusion pumps for hormones?
Becker KF; Allmeier H; Höllt V
Horm Metab Res; 1992 May; 24(5):210-3. PubMed ID: 1356900
[TBL] [Abstract][Full Text] [Related]
35. Molecular cytogenetics of multiple drug resistance.
Schoenlein PV
Cytotechnology; 1993; 12(1-3):63-89. PubMed ID: 7765332
[TBL] [Abstract][Full Text] [Related]
36. [Inhibition of ABC-transporter(s)' function in non-small cell lung cancer cells by platinum drugs].
Bogush TA; Konukhova AV; Ravcheeva AB; Zabotina TN; Kadagidze ZG; Bogush EA; Komov DV; Polotskiĭ BE; Laktionov KK; Davydov MI
Antibiot Khimioter; 2003; 48(10):11-5. PubMed ID: 15004974
[TBL] [Abstract][Full Text] [Related]
37. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
[TBL] [Abstract][Full Text] [Related]
38. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
Hatanaka H; Abe Y; Naruke M; Asai S; Miyachi H; Kawakami T; Nagata J; Kamochi J; Kijima H; Yamazaki H; Scanlon KJ; Ueyama Y; Nakamura M
Anticancer Res; 2001; 21(2A):879-85. PubMed ID: 11396179
[TBL] [Abstract][Full Text] [Related]
39. Multiple drug resistance in cancer therapy.
Schneider E; Cowan KH
Med J Aust; 1994 Mar; 160(6):371-3. PubMed ID: 7907772
[No Abstract] [Full Text] [Related]
40. Non P-glycoprotein novel proteins involved in human cancer multidrug resistance.
Baggetto LG
Bull Cancer; 1997 Apr; 84(4):385-90. PubMed ID: 9238162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
